SEARCH

SEARCH BY CITATION

Why Me?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

I was flattered when Keith Lindor asked me to contribute to the “Master's Perspective” series, especially when I saw the list of prior contributors, a “Who's-Who” of hepatology. It was reassuring that I was friends with all the prior contributors, collaborated with many of them, and was critically mentored by one of them (Alan Hofmann) (Fig. 1A). Indeed, as you will see later, my career in gastroenterology was also the result of a serendipitous opportunity1 that emerged when one of the other prior contributors (Al Czaja) had an unexpected change in his career plans. Thus, this essay will consist largely of personal anecdotes about the often unpredictable experiences and life-changing events that influenced my career as well as my science. In an effort to be helpful to younger colleagues, and with all humility and lack of presumption, I will also share some conclusions about how to develop a successful career in academic medicine.

thumbnail image

Figure 1. (A) Alan Hofmann, (B) Christian deDuve, (C) Bill Foulk on teaching rounds, (D) The BARF group. Arrows show Alan Hofmann and Nick LaRusso.

Download figure to PowerPoint

With that in mind, a key conclusion that I've come to from my experience as a physician-scientist (that might be useful to those of you who aspire to someday write your own “Master's Perspective”) is to develop a unique scientific niche that results in new and important information related to understanding and intervening indisease. To quote one of my mentors, the Nobel Laureate Christian de Duve (Fig. 1B), “…as scientists, we do not simply read the book of nature, we write it…”.2 Oh, and one other thing—it's important to hang around with really smart people! (Like the contributors to this series).

Why Medicine?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

Because of my Family, Dr. Melnick, and the Jesuits!

I grew up in Brooklyn, NY, the oldest of five. My parents were loving, supportive, and hard-working; neither had advanced beyond high school but both had great aspirations for and expectations of their children, especially their oldest son. As a Catholic boy raised in an Italian-American family, the professions that received the highest esteem were medicine and the clergy. Although the idea of becoming a priest entered my mind, it stayed there for less than 30 seconds! So, my earliest memories include the admiration and respect my parents had for physicians and the medical profession. Indeed, the unspoken, and occasionally spoken, idea that I would ultimately become a doctor was fairly pervasive even though none of my extended family were physicians. This not-so-subtle expectation was enhanced by my interactions with our family physician, Dr. Bernard Melnick. Melnick would visit our house (doctors still made house calls then) whenever I had a sore throat, which was often as a child, and regularly inject me with penicillin. Although I feared the injections, I was in awe of the confidence, compassion, and command that this individual displayed. He seemed to always be totally engaged, focused, and energized, and tried hard to alleviate my fears. On the occasions when we would visit his office, it was clean, well-organized, and efficient. So, my exposure to our family doctor provided me a concrete role model, a vision of what a doctor's life might be like, and the essence of what physicians did—they helped people!

As a teenager, I had the great privilege of attending Brooklyn Prep, an all-boys Jesuit college preparatory school, in the heart of Flatbush. Prep was one of four Jesuit high schools in New York City, was highly competitive, and required a challenging entrance exam. Students were predominantly first- and second-generation Italian-American, Irish-American, and Polish-American kids who, like me, were often the first in their families to aspire to a college education. The Jesuit curriculum “trained us for nothing, but prepared us for everything”.3 We entered as boys and left as educated young men. The three-century tradition of Jesuit education was based on the principal of “cura personalis”—care of the entire person. In practice, its distinguishing characteristics included a rigorous intellectual and athletic experience, an energetic and demanding academic environment, a focus on the common good, and a compassionate commitment to each individual in society. This enlightened environment and the challenging culture of personal development further encouraged my interest in medicine in at least three ways. First, I learned to be disciplined, focused, and able to multitask. Second, it emphasized what the essence of medicine was all about: helping others. And third, it instilled a sense of personal responsibility to society, what the Jesuits called “noblesse oblige”, which, loosely translated, means because we had been given so much, we had an obligation to give back. So, when I entered Boston College on an academic scholarship, medicine was my trajectory.

Any lesson in this story for you aspiring physician-scientists? Don't ever forget why you became a physician: to help people!

Why Mayo?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

Blame Bob Cattani, Bill Foulk, and Ralph Smith!

When I was a third-year medical student at New York Medical College working at Metropolitan Hospital in upper Manhattan, which was a wonderful environment for gaining confidence in taking care of very sick patients, my chief resident was a brilliant young internist named Bob Cattani. He had spent a short time at the Mayo Clinic before taking over my hospital team. As a result of this experience, he strongly encouraged me to apply for an externship at Mayo during my fourth year of medical school. He opined that the “blood and guts” medicine I was experiencing at Metropolitan Hospital, a huge indigent care facility dealing mainly with gunshot wounds, drug addiction, and alcohol-related illnesses, although critical to my evolution as a physician, could be refined and expanded by exposure to the Mayo model of care. With that in mind, I applied for and successfully obtained a 3-month externship at the Mayo Clinic during my fourth year of medical school.

In perhaps a foreordained and certainly fortuitous scenario, I was assigned to the Gastroenterology (GI) Division at the Mayo Clinic and made hospital rounds with Bill Foulk, Sid Phillips, and Dick Reitemier. I was enormously impressed by their depth of medical knowledge, their humility, their focus on the needs of the patient, and their commitment to education. The Mayo environment was a stark contrast to the intense and often competitive atmosphere I experienced in New York. The Mayo academic climate was relaxed, nurturing, and supportive; there were few examples of one-upmanship or self-promotion on rounds. The focus was always on how the team could most help the patient. An example of this was how Bill Foulk taught on rounds (Fig. 1C). Although he had written extensively on primary biliary cirrhosis (PBC), a disease which was just beginning to be defined, he rarely directly quoted his own literature contributions. Alternatively, in a rather matter-of-fact way, he gently communicated his enormous insights about this poorly understood syndrome, hardly ever mentioning the fact that he had been one of the earliest to recognize and describe the disease. Indeed, this was my first exposure to liver disease other than alcoholic liver disease, which was basically all I had seen in New York.

I was also exposed to Ralph Smith, a brilliant cardiologist who designed the first software programs for interpreting electrocardiograms (ECGs). I would spend part of each afternoon in the ECG laboratory reviewing hundreds of ECGs. After 2 weeks with Ralph, I could interpret just about any ECG pattern. This skill was particularly useful to me because my first rotation as an intern was in the Cardiac Intensive Care Unit at Metropolitan Hospital. Indeed, I became the go-to person among the house staff for complicated ECGs. I left Mayo in awe of the institution and the faculty, and determined to return for my residency training, which I subsequently did.

So, what if any lessons can be culled out of this experience? For your clinical training, go to the best places with the best people and choose anatmosphere that is most conducive to your learning style! The importance of this particular advice will come up again later.

Why Gastroenterology?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

Thank you, Al Czaja!

My residency experience at the Mayo Clinic following an internship at Metropolitan Hospital was outstanding. During those 2 years, I refined the clinical skills I had developed in an inner-city hospital by exposure to a wide spectrum of diseases and a superb group of attendings (at Mayo, they are called “consultants”). Unfortunately, I could not make a decision about a subspecialty as I approached the end of my residency primarily because I enjoyed just about every rotation I had experienced. As a result of my indecision, I tentatively planned a 1-year locum tenens in the region, primarily to earn money to help pay off my college and medical school loans. Then a serendipitous event occurred. Al Czaja, a world-renowned hepatologist and a previous contributor to the Master's Perspective series, was scheduled to enter a National Institutes of Health (NIH) GI Fellowship at Mayo. However, he got drafted; this was at the height of the Vietnam War, and doctors were in short supply. I was available because I had joined the army reserves, and was offered the “Czaja slot”. Because I had no other concrete plans, and had thoroughly enjoyed my GI rotations, I accepted. The NIH training grant, which Mayo had recently been awarded by NIH with Bill Summerskill as the principal investigator, required 2 years of full-time research followed by a year of clinical training.

The career lesson from this experience, if there is one, is that fate is often a major determining factor in one's career. Things happen in life that are totally unpredictable, and I would encourage a willingness to be flexible and alert to unexpected opportunities. To quote Carly Simon and James Taylor in their memorable rendition of “Mocking Bird”, sometimes you need “…to ride with the tide and go with the flow”.

Why Research?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

If You Know Alan Hofmann, the Answer Is Obvious!

Having accepted Czaja's position in the NIH training program, I entered the GI unit in 1972.The unit at that time was flourishing under the visionary leadership of Bill Summerskill and populated with such luminaries as Bill Go, Sid Phillips, Juan Malagelada, and my ultimate mentor, Alan Hofmann (Fig. 2). Alan accepted me into his group with some reluctance because I had virtually no research experience and some uncertainty about how committed I was to a career in research.

thumbnail image

Figure 2. GI Research Unit, July 1972.

Download figure to PowerPoint

My experience with Alan was life-changing; he was a constant source of ideas, always optimistic and encouraging, and a charismatic teacher. However, he traveled a lot. Thus, I was often left to my own skills at the bench which unfortunately were quite limited. One of Alan's senior fellows, Neville Hoffman, a brilliant scientist from Perth, Australia, took me under his wing and was critically important to my research evolution. It was a marvelous 2 years during which I studied biliary lipid secretion and bile acid metabolism in patients using creative intubation techniques and a new radioimmunoassay for serum bile acids developed in the GI unit.4–6 I began to consider the possibility that I might have something to contribute in research. It seemed I had an inquisitive and sometimes creative mind, and that my liberal arts education in high school and college prepared me well for communicating—I wrote effectively and clearly and lectured with increasing confidence.

A monumental turning point in my career happened one afternoon when Alan invited me to his house for a couple of beers after one of our lab meetings. These meetings occurred on Friday afternoons and were called the BARF meetings (BARF stood for Bile Acid Research Fellowship!) (Fig. 1D). Over more than a couple of beers, Alan gently suggested that, if I was serious about an independent research career, I should consider expanding my research training at a more basic level. He was sufficiently visionary to realize the importance of the evolving fields of cell and molecular biology to the future of research in general, and to GI research in particular. I accepted his advice with enthusiasm.

At that time, and to this day, the Mayo Clinic had a program called the Mayo Foundation Scholar Program; fellows who were identified as potential faculty were offered the opportunity to go elsewhere to learn new skills and bring them back to Mayo. And Mayo would assume all financial responsibility! The philosophy was based on the tradition started by the Mayo Brothers, who traveled all over the world to learn new things and bring them back to Rochester, MN. So with the support of Doug McGill, the division chief at the time, Alan arranged for me to visit laboratories at the NIH, Yale University, and his alma mater, the Rockefeller University. I presented seminars, met people, and talked science with the goal of deciding where I would spend my 2 years as a Mayo Foundation Scholar. The decision turned out to be an easy one. I was accepted as a Guest Investigator in the Department of Biochemical Cytology at the Rockefeller University, headed by Christian de Duve who had just been awarded the Nobel Prize for his work on cell fractionation and identification of the lysosome

In July 1975, I joined de Duve's laboratory and worked directly with two nurturing senior scientists in de Duve's group, Miklos Müller and Stanley Fowler. The more exposed I was to cell biology (I audited selective graduate courses at the Rockefeller University), the more I enjoyed research and the more confident I became that I could make a contribution. In part because my work with Alan had focused on biliary lipid secretion but also because I had published an article on biliary metal secretion,7 I continued to focus my attention on the liver during the Rockefeller years, basically trying to understand how molecules get into and out of hepatocytes.8

This experience taught me the importance of concentrated, extended research training; by the time I joined the faculty at Mayo, I had had a total of 4 years of full-time research training: two with Alan studying primarily humans, and two at the Rockefeller University, studying primarily cells and organelles. Moreover, I became conversant with a scientific discipline (i.e., cell biology). I emerged from my experience at the Rockefeller University with additional confidence and a perception of myself as a physician-scientist and an epithelial cell biologist.

What's the lesson here for aspiring physician-scientists? Get as much research training as possible with the best people in the best laboratories, and become fully conversant with a scientific discipline. And one more thing: be willing to take the advice of your mentors!

Why Clinical Hepatology?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

Because of Bill Summerskill, Doug McGill, and My Patients!

Although Alan was my primary research mentor, I published an article during my NIH fellowship with Bill Summerskill on chronic active hepatitis.9 This experience both exposed me to patients with this condition as well as to a master clinical hepatologist. I found I really liked seeing patients with liver disease, especially if, like Summerskill, I had something substantive to contribute to their care. During my third year of fellowship, which was primarily clinical, I worked almost exclusively with Doug McGill, the Division Chief, who had a practice focused entirely on liver disease. I saw a wide spectrum of liver disease with Doug, and my attraction to clinical hepatology continued to grow. Doug was also a master clinician conversant with the literature, but he had a pragmatic approach and could very quickly get to the bottom line, which suited my personality very well. My growing interest in liver also related to the fact that my research with Alan had focused on biliary lipid secretion, although at that time, the conceptual distinction between the parenchymal liver (i.e., that made up of hepatocytes) and the biliary tree (i.e., that made up of cholangiocytes) had not fully emerged. Nevertheless, given my initial research experience with Alan and then Bill, and my clinical training with Doug, hepatology was a natural area for my focus. Besides, and this is important, I was fascinated by the liver from a physiologic and pathophysiologic perspective at a time when hepatology was emerging as a distinct discipline within the science and practice of gastroenterology. So, hepatology became my shtick!

What's the lesson here? I think the most successful physician-scientists, regardless of how basic their research, maintain a continuous connection with patients. And ideally, the kinds of problems they see in their clinics provide the insights that spawn the hypotheses and questions they address in their labs. More on this below.

Why Cholangiocytes?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

Because of My Patients, My Fellows, and Some Good Luck!

During my postdoctoral research at the Rockefeller University, my work focused on hepatocytes. When I returned to Mayo and established my own laboratory, my initial R01 (research project grant) addressed the cellular mechanisms of hepatocyte secretion. My first independent contributions defined the excretory pathway within hepatocytes that were important in the transport of metals and in the disposition of cellular digestive products resulting from hepatocyte lysosomal degradation.10–16 The work was progressing very well due to the outstanding fellows that worked with me in the early years, including Rick Sewell, Greg Gores, Gene LeSage, and Jack Gross. As I was developing my laboratory, I also explored options for the focus of my clinical activities. Although I had significant protected time as a result of substantial hard money support from Mayo plus the rapid approval of my first R01, I enjoyed seeing patients and wanted to develop a focused area of clinical activity. The liver diseases that were attracting the most attention at that time, before the explosion of interest in viral hepatitis, were already the focus of Mayo colleagues. Rollie Dickson, Dick Fleming, Keith Lindor, and Jurgen Ludwig were defining the natural history of PBC; Bill Summerskill and Al Czaja were describing the clinical and biochemical features of autoimmune hepatitis; and what work was being done at Mayo in alcoholic and drug-induced liver disease was generally the purview of Doug McGill. So, my challenge was to find a disease that needed definition and clarification, that no one else at Mayo seemed to be interested in, and that I could use to help advance my career.

I settled on primary sclerosing cholangitis (PSC), probably for all the wrong reasons and not with a lot of initial support. The disease was esoteric and obscure, generally mentioned, if at all, in a single paragraph in most hepatology textbooks. Jurgen Ludwig, our superb hepatopathologist, told me that “…this disease simply does not exist because I have never seen a case at autopsy”. At any rate, a serendipitous partnership with a bright and very energetic GI fellow, Russ Wiesner, led to the publication of an important article describing the clinical, biochemical, and histologic features of patients with PSC seen at Mayo.17 With the advent of endoscopic retrograde cholangiopancreatography, which came along just at the right time for someone interested in studying PSC, and the resultant increase in its diagnosis, Russ, I, and many others at Mayo were able to generate a large series of studies that put this disease on the map,18–29 including the first randomized clinical trial in PSC.30 Thus, PSC became a well-recognized and increasingly diagnosed, albeit still idiopathic, cholestatic liver disease and Mayo became a major referral center for this syndrome. I seemed to have chosen well and at the right time, clearly more a matter of luck than brilliance!

While my laboratory was still primarily focused on the pathobiology of hepatocytes, I had somewhat of an insight for reasons that, quite frankly, I don't even remember. I hypothesized that the epithelial cells that lined the biliary tree were likely the target cells for many of the cholestatic liver diseases (PBC, PSC, cholangiocarcinoma, etc.) that were increasingly being seen in our clinics. Indeed, I had tucked away in my “idea file” years earlier that a future area for fruitful exploration might be understanding the biology of the cells that lined the biliary tree (we subsequently coined the term “cholangiocyte” for these cells at the first American Association for the Study of Liver Diseases [AASLD] Single Topic Conference on the Pathobiology of Biliary Epithelia that I coorganized with Al Sirica in 2000). The working hypothesis was, and still is, that a group of diseases, which we termed the “cholangiopathies”,31 could be conceptually clustered despite different etiologies, because their common final pathway was alteration in the phenotype of the cells that lined the biliary tree, i.e., the cholangiocytes (Table 1).

Table 1. Classification of Cholangiopathies
Genetic
 Alagille's syndrome
 Cystic fibrosis
 Fibropolycystic diseases (i.e., Caroli's syndrome, congenital hepatic fibrosis, adult dominant polycystic kidney disease, adult recessive polycystic kidney disease, adult dominant polycystic liver disease)
Immune-mediated
 Primary biliary cirrhosis
 Hepatic allograft rejection
 Graft-versus-host disease involving the liver
 Autoimmune cholangitis
Infectious
 Bacterial cholangitis
 Parasitic cholangitis
 Fungal cholangitis
 Viral cholangitis (i.e., acquired immune deficiency syndrome cholangiopathy)
Drug-induced (i.e., floxuridine-induced cholangiopathy)
Vascular/ischemic (i.e., post–liver transplantation hepatic artery stenosis)
Idiopathic
 Primary sclerosing cholangitis
 Biliary atresia
 Sarcoidosis
 Idiopathic childhood/adulthood ductopenia
Malignant
 Cholangiocarcinoma (i.e., bile duct adenocarcinoma)

The problem at the time, however, was that there were essentially no techniques available to study cholangiocytes. So, because scientific advances require techniques to answer questions and test hypotheses (a principle that de Duve often emphasized), I devoted a substantial amount of time and effort developing methodologies to investigate cholangiocyte biology (Fig. 3A),32–40 including an animal model of immune-mediated cholangitis.41 With those techniques in hand, and with the help of outstanding fellows (Moto Ishii, Akinobu Kato, Stuart Roberts, Gianfranco Alpini, Chee-Kiat Tan, Yoshi Ueno, John Phillips, Raul Marinelli, Flo Que, Kostas Lazaridis, Emanuella Cova, Ming Chen, Steve O'Hara, and Jonathan Dranoff) and superb technicians (Pam Tietz and Patrick Splinter), we began to systematically define the secretory, absorptive, and proliferative activities of cholangiocytes as well as the interaction of cholangiocytes with microbes. And wherever possible, we identified the proteins and signaling pathways responsible for these activities. Our strategy was always to first understand normal cholangiocyte function in order to allow the generation of hypotheses relevant to disease.42–66

thumbnail image

Figure 3. (A) Experimental models to study cholangiocyte biology. (a) Scanning electron micrograph of a group of isolated cholangiocytes after separation using immunomagnetic beads. Note that the prominent microvilli (arrowheads) are limited to one side of the cells. Magnification = 4400. (b) Transmission electron micrograph cross-section of normal rat cholangiocytes in culture demonstrates characteristics of polarized cells with apical microvilli (arrowheads) and numerous basolateral intercellular interdigitations near the collagen-coated filter denoted by asterisk (*) (bar = 2 mm, magnification = 7500). (c,d) Transmission electron micrograph of (c) apical and (d) basolateral plasma membrane domains revealed similar homogenous vesiculated membranes of varied shapes and sizes without apparent contamination of other organelles (bar = 0.5 μm, magnification = 22,500). (e) Three-dimensional reconstructed image of the intrahepatic biliary tree isolated from normal rat liver. (f) Light micrograph of an unstained isolated bile duct unit from rat liver. After overnight culture, the two ends seal to form an enclosed unit. A single layer of epithelial cells with a thin outer layer of connective tissue surrounds the lumen. (g) Microperfused intrahepatic bile duct unit isolated from rat liver, manually dissected and cannulated with micropipettes. (h) Transmission electron micrograph of C. parvum infection of cultured human cholangiocytes. A parasitophorous vacuole contains a developing parasite stage that is intracellular but extracytoplasmic. A macrogamete is shown in the inset, demonstrating development of sexual stages of the parasite. Bar = 1 mm. (B) Nick LaRusso at one of his lab meetings talking about cholangiocyte cilia.

Download figure to PowerPoint

So, what's the lesson here? Well, there are several, and they're all important. First, physician-scientists develop the questions they study in the laboratory from the patients they see in the clinic. Second, don't always listen to your senior colleagues (sorry Jurgen). Third, propose the questions and then make sure you develop the necessary techniques rather than the other way around (avoid the “have technique, looking for a question” approach). Finally, make sure you're having fun; insights require enthusiasm.

Why Medical Administration?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

Because of Bob Frye!

I never purposefully aspired to administrative leadership positions within academic medicine. Indeed, for the first 10 years of my career, I focused entirely on developing my laboratory and a focused clinical practice, and turned down multiple job opportunities as Division Chief at other institutions. However, in the late 1980s, Bob Frye, a world-renowned cardiologist, became the fourth Chair of the Department of Medicine (DOM) at the Mayo Clinic, and asked me to be his Vice-Chair for Research. By then, my laboratory was established and progressing well. In addition, I greatly admired Bob and felt strongly that under his leadership the DOM had the capacity to expand its research enterprise, and so I accepted the position. I found that I liked medical administration. I enjoyed both developing strategy and executing tactics, and found building something new was professionally rewarding (not unlike what one does in the laboratory). Indeed, colleagues have described my management style as one of “visionary pragmatism”; I like to decide where to go and then execute in getting there.

When the position of Chief of GI at the Mayo Clinic became open, I was offered the opportunity and accepted it with enthusiasm. I spent 9 years as Chief of GI and consider my major contributions to be doubling its size by recruiting outstanding individuals, expanding the research enterprise, and restructuring the division into interest groups and focused clinics. Because of the disciplined approach that I learned from the Jesuits (i.e., “age quod agis”, that is, “do what you're doing”), as well as my willingness to delegate to the outstanding individuals who helped me lead the division, especially Keith Lindor, I found that I could continue to expand my research program, maintain a focused clinical practice, and lead what ultimately evolved into the largest (some would say the best) division of gastroenterology, all at the same time. Moreover, I was privileged to become President of the AASLD during the 1990s, as well as editor of Gastroenterology. I loved what I would call the “structured variety” of my professional life; each day was different but the weeks had a definite balance and rhythm around research, practice, education, and administration. I divided the week into 10 half days and distributed my time in those buckets among these various responsibilities. Nevertheless, my professional identity was always that of a physician-scientist, and I was careful to assure adequate time and attention to my laboratory.

In 1999, I was offered the position as Chair of the DOM at Mayo, an opportunity, quite frankly, that I never seriously aspired to, but one that I accepted with great enthusiasm and excitement. My 9 years as Chair of the DOM were among the most satisfying of my professional life. With the help of superb vice and associate chairs, skilled administrators, and brilliant division chiefs, we developed an ambitious strategic plan for the department, doubled its size, increased NIH funding four-fold (moving our Department from 37th to 12th in NIH funding for departments of medicine) and undertook a major departmental restructuring through fusion of several existing divisions, establishment of new ones, and development of programs in aging, innovative health care delivery, clinical immunology and immunotherapeutics, integrative medicine, global health, translational immunobiology and biodefense, and professionalism. Many of these programs have subsequently evolved into centers serving the entire Mayo enterprise.

So, what have I learned from these experiences that might be of value to young colleagues? Try hard to get the right first job; I did and that is why I have never left Mayo. Make sure your laboratory is up and running successfully before you seriously consider major administrative responsibilities, however seductive having a titlemight seem. Be organized in the use of your time; your ideas and your time are your most valuable assets. Be open to opportunities that you may never have aspired to, but know who you are; in my case, I am always a physician-scientist. And make sure you have fun (I think I already said that but it is worth saying again).

What's Next?

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

Frankly, I Have No Idea!

My research program, being as objective as I can be, is thriving and remains the most satisfying component of my professional activities. We continue to develop new areas in cholangiocyte pathobiology based on the strategy that we need to understand how cholangiocytes function normally to generate hypotheses relevant to how their dysfunction might result in disease. Currently, the laboratory is heavily focused on the function and dysfunction of cholangiocyte primary cilia, an organelle that historically had been considered vestigial but more recently is recognized as critically important in development, cancer, and cystic kidney and liver disease (Fig. 3B). Our work has demonstrated that cholangiocytes express primary cilia that act as mechano-, chemo-, and osmosensors, display an array of key functionally important proteins, and are critical to normal cholangiocyte function and important in cystic liver disease.67-75 The work has often been devised and always executed by brilliant fellows (Anatoliy and Tetyana Masyuk, Sergio Gradilone, Jesus Banales) and superb technicians (Bing Huang, Angie Stroope, Gabriella Gajdos, Brynn Radke, and Christy Trussoni). Moreover, we have been able to identify molecular targets related to cystic liver disease that have already led to a successful clinical trial.76 In addition, we have begun to explore the role of small, noncoding RNAs in normal and abnormal cholangiocyte signaling,77–80 and we are developing hypotheses around the concept of the “activated cholangiocyte” and the consequences of this activation.

I remain grateful for the opportunity to continue to influence the lives of my younger colleagues. Throughout my career and the lineage of the laboratory, I have had the privilege to work with and mentor a myriad of students, technicians, and postdoctoral fellows. Their careers in the United States and abroad have followed successful trajectories leading to admission to medical school, establishment of their own independent laboratories, and appointments as professors, division chiefs, and department chairs. I remain in touch with many of them and continue to collaborate with some. I consider them my most important legacy.

My clinical activities now center primarily on a subset of the cholangiopathies, namely, biliary tract malignancies. Importantly, related laboratory efforts are focused on developing biomarkers for early detection of cholangiocarcinoma and relating abnormal ciliary function to the development of this devastating malignancy. Having stepped down as Chair of the DOM in mid-2008, I can now devote my time to new initiatives. Recently, we were awarded a Silvio O. Conte Digestive Diseases Center by NIH on Cell Signaling, of which I am the principal investigator. In addition, I am the medical director of the Mayo Clinic Center for Innovation, a new institutional initiative whose mission is to transform the experience and delivery of health care. This opportunity has provided me with a whole new set of exciting and interesting challenges and exposure to the evolving disciplines of innovation, design thinking, and entrepreneurship. I intend to continue all these activities as long as I and my colleagues (and the NIH) feel that I am making reasonable contributions. And, I approach the next phase of my career with excited interest in and curiosity about what the future holds.

Concluding Thoughts

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

I trust that this very personal perspective will inform some, inspire a few, not bore too many, and encourage those who read and reflect on it that the life of a physician-scientist is not a bad way to spend one's time. Discovering how cells normally work and what goes wrong when they become diseased, being able to make a difference in the lives of people suffering from sickness, helping to “write the book of nature”, working with very bright individuals and helping to promote the careers of younger colleagues, and building something that did not exist before is, to quote Ralph Waldo Emerson, “…to leave the world a bit better…and to have succeeded”. It is also a way to have a lot of fun!

Acknowledgements

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References

I would like to express my gratitude to Debbie Hintz and Pamela Tietz who helped with the preparation of this manuscript and to Alan Hofmann for providing me with Fig. 1D.

References

  1. Top of page
  2. Why Me?
  3. Why Medicine?
  4. Why Mayo?
  5. Why Gastroenterology?
  6. Why Research?
  7. Why Clinical Hepatology?
  8. Why Cholangiocytes?
  9. Why Medical Administration?
  10. What's Next?
  11. Concluding Thoughts
  12. Acknowledgements
  13. References
  • 1
    Lazaridis KN, Gores GJ. Our new president–Nicholas F. LaRusso, MD. Gastroenterology 2007; 132: 2005-2011.
  • 2
    de Duve C. Singularities: Landmarks on the Pathways of Life. Cambridge, UK: Cambridge University Press; 2005.
  • 3
    Sesna F. Middlebury College (Middlebury, VT) Commencement Speech. 1996.
  • 4
    LaRusso NF, Hoffman NE, Hofmann AF, Northfield TC, Thistle JL. Effect of primary bile acid ingestion on bile acid metabolism and biliary lipid secretion in gallstone patients. Gastroenterology 1975; 69: 1301-1314.
  • 5
    LaRusso NF, Szczepanik PA, Hofmann AF. Effect of deoxycholic acid ingestion on bile acid metabolism and biliary lipid secretion in normal subjects. Gastroenterology 1977; 72: 132-140.
  • 6
    LaRusso NF, Hoffman NE, Hofmann AF, Korman MG. Validity and sensitivity of an intravenous bile acid tolerance test in patients with liver disease. N Engl J Med 1975; 292: 1209-1214.
  • 7
    van Berge Henegouwen GP, Tangedahl TN, Hofmann AF, Northfield TC, LaRusso NF, McCall JT. Biliary secretion of copper in healthy man: quantitation by an intestinal perfusion technique. Gastroenterology 1977; 72: 1228-1231.
  • 8
    LaRusso NF, Fowler S. Coordinate secretion of acid hydrolases in rat bile: Hepatocyte exocytosis of lysosomal protein? J Clin Invest 1979; 64: 948-954.
  • 9
    LaRusso NF, Summerskill WHJ, McCall JC. Abnormalities of chemical tests for copper metabolism in chronic active liver disease: differentiation from Wilson's disease. Gastroenterology 1976; 70: 653-655.
  • 10
    Sewell RB, Barham SS, LaRusso NF. Effect of chloroquine on the form and function of hepatocyte lysosomes: morphologic modifications and physiologic alterations related to the biliary excretion of lipids and proteins. Gastroenterology 1983; 85: 1146-1153.
  • 11
    Novikoff PM, LaRusso NF, Novikoff AB, Stockert RJ, Yam A, LeSage GD. Immunocytochemical localization of lysosomal β-galactosidase in rat liver. J Cell Biol 1983; 97: 1559-1565.
  • 12
    Gores GJ, LaRusso NF, Miller LJ. Hepatic processing of cholecystokinin peptides: I. Structural specificity and mechanism of hepatic extraction. Am J Physiol 1986; 250: G344-G349.
  • 13
    Gores GJ, Miller LJ, LaRusso NF. Hepatic processing of cholecystokinin peptides: II. Cellular metabolism, transport, and biliary excretion. Am J Physiol 1986; 250: G350-G356.
  • 14
    LeSage GD, Kost LJ, Barham SS, LaRusso NF. Biliary excretion of iron from hepatocyte lysosomes in the rat: a major excretory pathway in experimental iron overload. J Clin Invest 1986; 77: 90-97.
  • 15
    Sewell RB, Grinpukel SA, Zinsmeister AR, LaRusso NF. Pharmacologic perturbation of rat liver lysosomes: effects on release of lysosomal enzymes and of lipids into bile. Gastroenterology 1988; 95: 1088-1098.
  • 16
    Gross JB, Myers BM, Kost LJ, Kuntz SM, LaRusso NF. Biliary copper excretion by hepatocyte lysosomes in the rat: major excretory pathway in experimental copper overload. J Clin Invest 1989; 83: 30-39.
  • 17
    Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-206.
  • 18
    Quigley EM, LaRusso NF, Ludwig J, MacSween RNM, Birnie GG, Watkinson G. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1983; 85: 1160-1165.
  • 19
    MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J. Primary sclerosing cholangitis: Findings on cholangiography and pancreatography. Radiology 1983; 149: 39-44.
  • 20
    Wiesner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985; 88: 108-114.
  • 21
    Gross JB, Ludwig J, Wiesner RH, McCall JT, LaRusso NF. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 1985; 89: 272-278.
  • 22
    MacCarty RL, LaRusso NF, May GR, Bender CE, Wiesner RH, King JE, Coffey RJ. Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. Radiology 1985; 156: 43-46.
  • 23
    Wiesner RH, LaRusso NF, Dozois RR, Beaver SJ. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis. Gastroenterology 1986; 90: 316-322.
  • 24
    Cangemi JR, Wiesner RH, Beaver SJ, Ludwig J, MacCarty RL, Dozois RR, Zinsmeister AR, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989; 96: 790-794.
  • 25
    Wiesner RH, Grambsch P, Dickson ER, Ludwig J, McCarty R, Hunter EB, Fleming TR, et al. Primary sclerosing cholangitis: natural history, prognostic factors, and survival analysis. HEPATOLOGY 1989; 10: 430-436.
  • 26
    Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ Jr, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213: 21-25.
  • 27
    Hay JE, Lindor KD, Wiesner RH, Dickson ER, Krom RAF, LaRusso NF. The metabolic bone disease of primary sclerosing cholangitis. HEPATOLOGY 1991; 14: 257-261.
  • 28
    Sandborn JW, Wiesner RH, Tremaine WJ, LaRusso NF. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993; 34: 242-246.
  • 29
    Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19–9 in the diagnosis of cholangiocarcinoma in patients without primary sclerosing cholangitis. Gastroenterology 2000; 95: 204-207.
  • 30
    LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988; 95: 1036-1042.
  • 31
    Lazaridis KN, Strazzabosco M, LaRusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004; 127: 1565-1577.
  • 32
    Ishii M, Vroman B, LaRusso NF. Isolation and morphologic characterization of bile duct epithelial cells from normal rat liver. Gastroenterology 1989; 97: 1236-1247.
  • 33
    Roberts SK, Kuntz SM, Gores GJ, LaRusso NF. Regulation of bicarbonate-dependent ductular bile secretion assessed by lumenal micropuncture of isolated rodent intrahepatic bile ducts. Proc Natl Acad Sci U S A 1993; 90: 9080-9084.
  • 34
    Tietz PS, Holman RT, Miller LJ, LaRusso NF. Isolation and characterization of rat cholangiocyte vesicles enriched in apical or basolateral plasma membrane domains. Biochemistry 1995; 34: 15436-15443.
  • 35
    Vroman B, LaRusso NF. Development and characterization of polarized primary cultures of rat intrahepatic bile duct epithelial cells. Lab Invest 1996; 74: 303-313.
  • 36
    Tietz P, Levine S, Holman R, Fretham C, LaRusso NF. Characterization of apical and basolateral plasma membrane domains derived from cultured rat cholangiocytes. Anal Biochem 1997; 254: 192-199.
  • 37
    Ludwig J, Ritman EL, LaRusso NF, Sheedy PF, Zumpe G. Anatomy of the human biliary system studied by quantitative computer-aided three-dimensional imaging techniques. HEPATOLOGY 1998; 27: 893-899.
  • 38
    de Groen PC, Vroman B, Laakso K, LaRusso NF. Characterization and growth regulation of a rat intrahepatic bile duct epithelial cell line under hormonally defined, serum-free conditions. In Vitro Cell Dev Biol Anim 1998; 34: 704-710.
  • 39
    Masyuk AI, Gong AY, Kip S, Burke MJ, LaRusso NF. Perfused rat intrahepatic bile ducts secrete and absorb water, solute, and ions. Gastroenterology 2000; 119: 1672-1680.
  • 40
    Masyuk TV, Ritman EL, LaRusso NF. Quantitative assessment of the rat intrahepatic biliary system by three-dimensional reconstruction. Am J Pathol 2001; 158: 2079-2088.
  • 41
    Ueno Y, Phillips JO, Ludwig J, Lichtman SN, LaRusso NF. Development and characterization of a rodent model of immune-mediated cholangitis. Proc Natl Acad Sci U S A 1996; 93: 216-220.
  • 42
    Cova E, Gong A, Marinelli RA, LaRusso NF. Water movement across rat bile duct units is transcellular and channel-mediated. HEPATOLOGY 2001; 34: 456-463.
  • 43
    Ishii M, Vroman B, LaRusso NF. Morphologic demonstration of receptor-mediated endocytosis of epidermal growth factor by isolated bile duct epithelial cells. Gastroenterology 1990; 98: 1284-1291.
  • 44
    Kato A, Gores GJ, LaRusso NF. Secretin stimulates exocytosis in isolated bile duct epithelial cells by a cyclic AMP-mediated mechanism. J Biol Chem 1992; 267: 15523-15529.
  • 45
    Roberts SK, Yano M, Ueno Y, Pham L, Alpini G, Agre P, LaRusso NF. Cholangiocytes express aquaporin CHIP and transport water via a channel-mediated mechanism. Proc Natl Acad Sci U S A 1994; 91: 13009-13013.
  • 46
    Tietz PS, Alpini G, Pham LD, LaRusso NF. Somatostatin inhibits secretin-induced ductal hypercholeresis and exocytosis by cholangiocytes. Am J Physiol 1995; 269: G110-G118.
  • 47
    Tan CK, Podila PV, Taylor JE, Nagorney DM, Wiseman GA, Gores GJ, LaRusso NF. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 1995; 108: 1908-1916.
  • 48
    Alpini G, Ulrich C, Roberts S, Phillips JO, Ueno Y, Podila PV, Colegio O, et al. Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am J Physiol 1997; 272: G289-G297.
  • 49
    Marinelli R, Pham L, Agre P, LaRusso NF. Secretin promotes osmotic water transport in rat cholangiocytes by increasing aquaporin-1 water channels in plasma membrane: Evidence for a secretin-induced vesicular translocation of aquaporin-1. J Biol Chem 1997; 272: 12984-12988.
  • 50
    Lazaridis KN, Pham L, Tietz P, Marinelli RA, de Groen PC, Levine S, Dawson PA, et al. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J Clin Invest 1997; 100: 2714-2721.
  • 51
    Marinelli RA, Tietz PS, Pham LD, Rueckert L, Agre P, LaRusso NF. Secretin induces the apical insertion of aquaporin-1 water channels in rat cholangiocytes. Am J Physiol 1999; 276: G280-G286.
  • 52
    Chen XM, LaRusso NF. Mechanisms of attachment and internalization of Cryptosporidium parvum to biliary and intestinal epithelial cells. Gastroenterology 2000; 118: 368-379.
  • 53
    Marinelli RA, Pham LD, Tietz PS, LaRusso NF. Expression of aquaporin-4 water channels in rat cholangiocytes. HEPATOLOGY 2000; 31: 1313-1317.
  • 54
    Chen XM, Levine SA, Splinter PL, Tietz PS, Ganong AL, Jobin C, Gores GJ, et al. Cryptosporidium parvum activates nuclear factor κB in biliary epithelia preventing epithelial cell apoptosis. Gastroenterology 2001; 120: 1774-1783.
  • 55
    Gong AY, Masyuk AI, Splinter PL, Huebert RC, Tietz PS, LaRusso NF. Channel-mediated water movement across enclosed or perfused mouse intrahepatic bile duct units. Am J Physiol 2002; 283: C338-C346.
  • 56
    Masyuk AI, Masyuk TV, Tietz PS, Splinter PL, LaRusso NF. Intrahepatic bile ducts transport water in response to absorbed glucose. Am J Physiol 2002; 283: C785-C791.
  • 57
    Gong AY, Tietz PS, Muff MA, Splinter PL, Huebert RC, Strowski MZ, Chen XM, et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am J Physiol 2003; 184: C1205-C1214.
  • 58
    Tietz PS, Marinelli RA, Chen XM, Cohn J, Kole J. McNiven MA, LaRusso NF. Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes. J Biol Chem 2003; 278: 20413-20419.
  • 59
    Chen XM, Huang BQ, Splinter PL, Cao H, Zhu Z, McNiven MA, LaRusso NF. Cryptosporidium parvum invasion of biliary epithelia requires host-cell tyrosine phosphorylation of cortactin via c-Src. Gastroenterology 2003; 125: 216-228.
  • 60
    Marinelli RA, Tietz PS, Caride AJ, Huang BQ, LaRusso NF. Water transporting properties of hepatocyte, basolateral and canalicular plasma membrane domains. J Biol Chem 2003; 278: 43157-43162.
  • 61
    Splinter PL. Masyuk AI, Marinelli RA, LaRusso NF. AQP4 transfected into mouse cholangiocytes promotes water transport in biliary epithelia. HEPATOLOGY 2004; 39: 109-116.
  • 62
    Chen XM, Splinter PL, Tietz PS, Huang BQ, Billadeau DD, LaRusso NF. Phosphatidylinositol 3 kinase and frabin mediate Cryptosporidium parvum cellular invasion via activation of Cdc42. J Biol Chem 2004; 279: 31671-31678.
  • 63
    Chen XM, O'Hara SP, Huang BQ, Splinter PL, Nelson JB, LaRusso NF. Localized glucose and water influx facilitates cryptosporidium parvum cellular invasion by means of modulation of host-cell membrane protrusion. Proc Natl Acad Sci U S A 2005; 102: 6338-6343.
  • 64
    Tietz P, Jefferson J, Pagano R, LaRusso NF. Membrane microdomains in hepatocytes: potential target areas for proteins involved in canalicular bile secretion. J Lipid Res 2005; 46: 1426-1432.
  • 65
    Chen XM, O'Hara SP, Nelson JP, Splinter PL, Small AJ, Tietz PS, Limper AH, et al. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation in NF-kB. J Immunol 2005; 175: 7447-7456.
  • 66
    Mazzone A, Tietz PS, Jefferson JJ, Pagano R, LaRusso NF. Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes. H Epatology 2006; 43: 287-296.
  • 67
    Masyuk TV, Huang BQ, Ward CJ, Masyuk AI, Yuan D, Splinter PL, Punyashthiti R, et al. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 2003; 125: 1303-1310.
  • 68
    Huang BQ, Masyuk TV, Muff MA, Tietz PS, Masyuk AI, LaRusso NF. Isolation and characterization of cholangiocyte primary cilia. Am J Physiol 2006; 291: G500-G509.
  • 69
    Masyuk AI, Masyuk TV, Splinter PL, Huang BQ, Stroope AJ, LaRusso NF. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 2006; 131: 911-920.
  • 70
    Masyuk TV, Masyuk AI, Torres VE, Harris PC, LaRusso NF. Octreotide inhibits hepatic cystogenesis and fibrosis by reduction of cholangiocyte cAMP: a potential therapeutic approach for the polycystic liver diseases. Gastroenterology 2007; 132: 1104-1116.
  • 71
    Gradilone SA, Masyuk AI, Splinter PL, Banales JM, Huang BQ, Tietz PS, Masyuk TV, et al. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity including bicarbonate secretion. Proc Natl Acad Sci, U S A 2007; 104: 19138-19143.
  • 72
    Masyuk AI, Gradilone SA, Banales JM, Huang BQ, Masyuk TV, Lee SO, Splinter PL, et al. Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. Am J Physiol 2008; 295: G725-G734.
  • 73
    Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF. The cAMP effectors EPAC and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). HEPATOLOGY 2009; 49: 160-174.
  • 74
    Gradilone SA, Masyuk TV, Huang BQ, Banales JM. Lehmann GL, Radtke BN, Stroope A, et al. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD. Gastroenterology 2010; 139: 304-314.
  • 75
    Masyuk AI, Huang BQ, Ward CJ, Gradilone SA, Banales JM, Masyuk TV, Radtke B, et al. Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am J Physiol 2010; 299: G990-G999.
  • 76
    Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-1061.
  • 77
    Splinter PL, Masyuk AI, LaRusso NF. Specific inhibition of AQP1 water channels in isolated rat intrahepatic bile duct units by small interfering RNAs. J Biol Chem 2003; 278: 6268-6274.
  • 78
    Chen XM, Splinter PL, O'Hara SP, LaRusso NF. A cellular miRNA, let-7i, regulates toll-like receptor 4 expression and contributes to cholangiocyte immune response against cryptosporidium parvum infection. J Biol Chem 2007; 282: 28929-28938.
  • 79
    Lee SO, Masyuk TV, Splinter PL, Masyuk AI, Stroope AJ, LaRusso NF. MicroRNA-15a regulates the expression of the cell-cycle regulator cdc25a affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest 2008; 118: 3714-3724.
  • 80
    O'Hara SP, Splinter PL, Gajdos GB, Trussoni CE, Fernandez-Zapico ME, Chen XM, LaRusso NF. NFκB p50-CCAAT/enhancer-binding protein β (C/EBPβ)-mediated transcriptional repression of microRNA let-7i following microbial infection. J Biol Chem 2010; 285: 216-225.